Background: The induction chemotherapy regimen for acute myeloid leukemia has evolved as once induction is
completed patients progress through the consolidation phase and achieve remission in 76% of cases. For patients
with relapsed or refractory disease, alternative chemotherapy agents are available. Monoclonal antibody therapy
with biological agents, such as the immunotoxin gemtuzumab ozog...